Overview
NERV market data
Price History
NERV price chart
Valuation & Profitability
- P/E (TTM)
- 129.98 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.19 Diluted earnings per share over the trailing twelve months.
- Beta
- -0.11 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 4.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.76 – $12.46 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $187.2M · P/B 4.28.
Company News
Minerva Neurosciences shares are trading higher after Jefferies upgraded the stock from Hold to Buy rating and raised the price target from $7.5 to $10.Benzinga · Aug 14, 2026, 6:01 PM
This Capricor Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For FridayBenzinga · Aug 14, 2026, 12:55 PM
Jefferies Upgrades Minerva Neurosciences to Buy, Raises Price Target to $10Benzinga · Aug 14, 2026, 12:41 PM
Minerva Neurosciences Q2 Adj. EPS $(0.10) Beats $(0.12) EstimateBenzinga · Aug 7, 2026, 11:42 AM
8-K filing — Minerva Neurosciences, Inc. (NERV)SEC EDGAR · Aug 7, 2026, 11:13 AM
CORRECTION: Minerva Neurosciences Establishes $75M At-The-Market Stock Offering Program With Leerink PartnersBenzinga · May 27, 2026, 9:00 PM
Minerva Neurosciences To Offer Up To $75M In Common Stock OfferingBenzinga · May 27, 2026, 8:55 PM